CN115244042A - 吲唑类衍生物及其制备方法和应用 - Google Patents

吲唑类衍生物及其制备方法和应用 Download PDF

Info

Publication number
CN115244042A
CN115244042A CN202180018079.9A CN202180018079A CN115244042A CN 115244042 A CN115244042 A CN 115244042A CN 202180018079 A CN202180018079 A CN 202180018079A CN 115244042 A CN115244042 A CN 115244042A
Authority
CN
China
Prior art keywords
alkyl
membered
cycloalkyl
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180018079.9A
Other languages
English (en)
Inventor
冯焱
李世强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Lingtai Biomedical Technology Co ltd
Original Assignee
Shanghai Lingtai Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Lingtai Biomedical Technology Co ltd filed Critical Shanghai Lingtai Biomedical Technology Co ltd
Publication of CN115244042A publication Critical patent/CN115244042A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

提供了一类靶向IRAK4激酶蛋白降解的吲唑类衍生物、及其制备方法和应用。具体涉及式Ⅰ化合物、其制备方法、及其药物组合物和应用，其中所述Ra、Rb、Rc、Rd、Re、n、环A、环B、L、环C、X、W如说明书中所定义。所述化合物能够显著的降解细胞中的IRAK4激酶蛋白，可用作制备治疗和/或预防由IRAK4介导的相关疾病或病症的药物，如癌症、免疫性疾病和炎性疾病。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN202180018079.9A 2020-10-26 2021-02-04 吲唑类衍生物及其制备方法和应用 Pending CN115244042A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011157779X 2020-10-26
CN202011157779 2020-10-26
PCT/CN2021/075341 WO2022088551A1 (zh) 2020-10-26 2021-02-04 吲唑类衍生物及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN115244042A true CN115244042A (zh) 2022-10-25

Family

ID=81381811

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180018079.9A Pending CN115244042A (zh) 2020-10-26 2021-02-04 吲唑类衍生物及其制备方法和应用

Country Status (5)

Country Link
US (1) US20230192655A1 (zh)
EP (1) EP4238968A1 (zh)
JP (1) JP7474527B2 (zh)
CN (1) CN115244042A (zh)
WO (1) WO2022088551A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025159A1 (zh) * 2021-08-23 2023-03-02 上海领泰生物医药科技有限公司 Irak4降解剂及其制备方法和应用
WO2023116920A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
WO2023241644A1 (zh) * 2022-06-15 2023-12-21 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
CN117777126A (zh) * 2022-09-29 2024-03-29 武汉人福创新药物研发中心有限公司 作为irak4降解剂的咪唑并吡啶类化合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2020113233A1 (en) * 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN114502158A (zh) * 2019-06-28 2022-05-13 凯麦拉医疗公司 Irak降解剂及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11167043B2 (en) 2017-12-20 2021-11-09 Translate Bio, Inc. Composition and methods for treatment of ornithine transcarbamylase deficiency
CA3090275A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2020113233A1 (en) * 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN114502158A (zh) * 2019-06-28 2022-05-13 凯麦拉医疗公司 Irak降解剂及其用途

Also Published As

Publication number Publication date
WO2022088551A1 (zh) 2022-05-05
JP2023529108A (ja) 2023-07-07
US20230192655A1 (en) 2023-06-22
EP4238968A1 (en) 2023-09-06
JP7474527B2 (ja) 2024-04-25

Similar Documents

Publication Publication Date Title
CN115244042A (zh) 吲唑类衍生物及其制备方法和应用
US9493440B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
TWI813666B (zh) 一種多功能化合物、其製備方法及其在醫藥上的應用
CN111909140A (zh) 作为tyk2抑制剂的杂环化合物及合成和使用方法
JP6746613B2 (ja) ウレア誘導体、またはその薬理学的に許容される塩
WO2013161851A1 (ja) ベンズアミド誘導体
WO2023174175A1 (zh) Kif18a抑制剂
CN113582980A (zh) 基于杂环和戊二酰亚胺骨架的化合物及其应用
AU2017294208B2 (en) Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof
JP2022517723A (ja) Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
TWI833104B (zh) 靶向蛋白降解化合物及其製備方法和應用
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
KR20180022992A (ko) 브로모도메인 억제제로서 바이사이클릭 헤테로사이클 유도체
US9078899B2 (en) Pyrazolyl-based carboxamides II
JPH03505204A (ja) ３環式３―オキソ―プロパンニトリル誘導体およびその調製方法
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
KR20230133396A (ko) Rip2 키나아제 억제제로서의 헤테로아릴 화합물, 이의 조성물 및 용도
WO2023165574A1 (zh) 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
JP7414550B2 (ja) （ヘテロ）アリールイミダゾロン化合物
WO2021182491A1 (ja) ヒポキサンチン化合物の結晶
WO2024094190A1 (zh) Irak4降解剂及其用途
WO2024032673A1 (zh) Pde4b抑制剂及其用途
WO2023083373A1 (zh) 作为Src抑制剂的化合物
WO2023025159A1 (zh) Irak4降解剂及其制备方法和应用
WO2023208174A1 (zh) 去泛素化酶抑制剂及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination